On March 07, 2025, in Rochester, New York, Vaccinex, Inc. (OTC: VCNX) revealed its plan to remove its common stock from the Nasdaq. The clinical-stage biotech firm focuses on tackling neurodegenerative diseases by targeting astrogliosis and neuroinflammation via SEMA4D inhibition. The stock's Nasdaq trading halt commenced on December 18, 2024.
